SEC Comment Letter 0000000000-24-002066 to Lite Strategy, Inc. (LITS)
Lite Strategy, Inc.
Date: Feb. 23, 2024 · CIK: 0001262104 · Accession: 0000000000-24-002066
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-277201
Letter
United States securities and exchange commission logo February 23, 2024 David M. Urso President & Chief Executive Officer MEI Pharma, Inc. 11455 El Camino Real Suite 250 San Diego, California 92130 Re:MEI Pharma, Inc. Registration Statement on Form S-3 Filed February 20, 2024 File No. 333-277201 Dear David M. Urso: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Justin W. Chairman, Esq.
Show Raw Text
United States securities and exchange commission logo
February 23, 2024
David M. Urso
President & Chief Executive Officer
MEI Pharma, Inc.
11455 El Camino Real Suite 250
San Diego, California 92130
Re:MEI Pharma, Inc.
Registration Statement on Form S-3
Filed February 20, 2024
File No. 333-277201
Dear David M. Urso:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Justin W. Chairman, Esq.